News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
862,949 Results
Type
Article (87534)
Company Profile (809)
Press Release (774583)
Multimedia
Podcasts (178)
Webinars (28)
Section
Business (233097)
Career Advice (4140)
Deals (39812)
Drug Delivery (140)
Drug Development (91282)
Employer Resources (203)
FDA (18297)
Job Trends (17407)
News (397490)
Policy (39929)
Tag
Academia (3005)
Academic (2)
Accelerated approval (18)
Adcomms (35)
Allergies (130)
Alliances (56980)
ALS (147)
Alzheimer's disease (1691)
Antibody-drug conjugate (ADC) (267)
Approvals (18338)
Artificial intelligence (515)
Autoimmune disease (104)
Automation (30)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (167)
Biotechnology (485)
Bladder cancer (139)
Brain cancer (53)
Breast cancer (528)
Cancer (4175)
Cardiovascular disease (361)
Career advice (3562)
Career pathing (38)
CAR-T (259)
CDC (57)
Cell therapy (713)
Cervical cancer (33)
Clinical research (75822)
Collaboration (1450)
Company closure (4)
Compensation (964)
Complete response letters (63)
COVID-19 (2964)
CRISPR (85)
C-suite (627)
Cystic fibrosis (142)
Data (4950)
Decentralized trials (2)
Denatured (64)
Depression (114)
Diabetes (467)
Diagnostics (7111)
Digital health (38)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (247)
Drug pricing (195)
Drug shortages (36)
Duchenne muscular dystrophy (209)
Earnings (99244)
Editorial (55)
Employer branding (25)
Employer resources (172)
Events (133534)
Executive appointments (998)
FDA (20895)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (16)
Funding (1305)
Gene editing (181)
Generative AI (52)
Gene therapy (568)
GLP-1 (1041)
Government (5393)
Grass and pollen (8)
Guidances (374)
Healthcare (20939)
HIV (49)
Huntington's disease (41)
IgA nephropathy (67)
Immunology and inflammation (257)
Immuno-oncology (22)
Indications (59)
Infectious disease (3214)
Inflammatory bowel disease (192)
Inflation Reduction Act (16)
Influenza (102)
Intellectual property (201)
Interviews (816)
IPO (17931)
IRA (59)
Job creations (5197)
Job search strategy (2866)
Kidney cancer (17)
Labor market (81)
Layoffs (643)
Leadership (37)
Legal (10151)
Liver cancer (92)
Longevity (13)
Lung cancer (592)
Lymphoma (286)
Machine learning (33)
Management (66)
Manufacturing (674)
MASH (147)
Medical device (14914)
Medtech (14941)
Mergers & acquisitions (22788)
Metabolic disorders (1196)
Multiple sclerosis (141)
NASH (23)
Neurodegenerative disease (238)
Neuropsychiatric disorders (63)
Neuroscience (2767)
NextGen: Class of 2025 (7689)
Non-profit (5098)
Now hiring (60)
Obesity (576)
Opinion (316)
Ovarian cancer (142)
Pain (173)
Pancreatic cancer (179)
Parkinson's disease (245)
Partnered (32)
Patents (432)
Patient recruitment (340)
Peanut (57)
People (66368)
Pharmaceutical (145)
Pharmacy benefit managers (29)
Phase I (23386)
Phase II (32896)
Phase III (24814)
Pipeline (2906)
Policy (302)
Postmarket research (3554)
Preclinical (10569)
Press Release (72)
Prostate cancer (205)
Psychedelics (52)
Radiopharmaceuticals (282)
Rare diseases (715)
Real estate (7423)
Recruiting (79)
Regulatory (28146)
Reports (65)
Research institute (2696)
Resumes & cover letters (651)
Rett syndrome (17)
RNA editing (15)
RSV (76)
Schizophrenia (140)
Series A (215)
Series B (160)
Service/supplier (30)
Sickle cell disease (85)
Special edition (26)
Spinal muscular atrophy (170)
Sponsored (42)
Startups (4319)
State (2)
Stomach cancer (17)
Supply chain (103)
Tariffs (96)
The Weekly (112)
Vaccines (1064)
Venture capital (68)
Weight loss (406)
Women's health (61)
Worklife (21)
Date
Today (337)
Last 7 days (1035)
Last 30 days (3334)
Last 365 days (33734)
2025 (28485)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1284)
Alabama (81)
Alaska (7)
Arizona (309)
Arkansas (14)
Asia (51079)
Australia (8981)
California (9915)
Canada (2942)
China (951)
Colorado (416)
Connecticut (438)
Delaware (285)
Europe (117406)
Florida (1457)
Georgia (326)
Hawaii (3)
Idaho (67)
Illinois (830)
India (55)
Indiana (488)
Iowa (20)
Japan (339)
Kansas (127)
Kentucky (39)
Louisiana (22)
Maine (79)
Maryland (1320)
Massachusetts (7427)
Michigan (320)
Minnesota (589)
Mississippi (4)
Missouri (124)
Montana (33)
Nebraska (26)
Nevada (110)
New Hampshire (80)
New Jersey (2742)
New Mexico (32)
New York (2668)
North Carolina (1448)
North Dakota (10)
Northern California (4564)
Ohio (310)
Oklahoma (22)
Oregon (51)
Pennsylvania (2049)
Puerto Rico (20)
Rhode Island (46)
South America (1655)
South Carolina (52)
South Dakota (1)
Southern California (3782)
Tennessee (153)
Texas (1550)
United States (36424)
Utah (299)
Virginia (255)
Washington D.C. (84)
Washington State (843)
West Virginia (4)
Wisconsin (103)
Wyoming (2)
There are 862,949 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama
Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company reported third-quarter earnings. A rough quarter underscored the stakes for the Danish pharma.
November 5, 2025
·
5 min read
·
Annalee Armstrong
Arnatar Therapeutics
Arnatar Therapeutics develops RNA-based medicines that either turn down the expression of harmful genes or turn up the expression of missing proteins to treat serious diseases with limited or no current treatment options.
Antag Therapeutics
Antag Therapeutics is a biopharmaceutical company that develops innovative, peptide-based GIP receptor antagonist therapies for the treatment of obesity and related cardiometabolic diseases.
Press Releases
Cardiol Therapeutics’ Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
- The ESC M&PD meeting brings together the world’s experts working to improve the treatment of myocarditis and pericarditis. - Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass. - The Company will host a webcast conference call on December 1, 2025, to discuss the ARCHER findings and their significance, and to highlight the positive implications for Cardiol’s programs in inflammatory heart disease.
November 5, 2025
·
7 min read
Podcast
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
Pfizer and Novo Nordisk continue to fight for ownership of obesity startup Metsera; CDER Director George Tidmarsh leaves his position amid an ongoing probe into his “personal conduct”; FDA reverses course on approval requirements for uniQure’s Huntington’s gene therapy; Sarepta’s exon-skipping Duchenne muscular dystrophy drugs fail confirmatory study.
November 5, 2025
·
1 min read
·
Heather McKenzie
Press Releases
Life Science Market Size Worth USD 278.40 Billion by 2034
November 5, 2025
·
1 min read
Press Releases
Antifungal Drugs Market Size to Worth USD 24.25 Billion by 2034
November 5, 2025
·
1 min read
Press Releases
FireGate Biotech, a Veteran-Founded Life Sciences Company, Announces Launch and Early Research Program Focused on Immune Modulation
November 5, 2025
·
1 min read
Rare diseases
Biohaven Cuts R&D Spending by 60% After FDA Rejection of Drug for Rare Neurodegenerative Disease
Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.
November 5, 2025
·
2 min read
·
Tristan Manalac
Events
Advancing AAV Vector Production with High-Integrity DNA Constructs
Explore how optimized DNA constructs drive more efficient, reproducible AAV production. You’ll learn: • How a 2-plasmid system reduces complexity • How ITR integrity impacts AAV yield and purity • Why Minicircle DNA enhances AAV production efficiency Speaker: Dr. Ram Shankar, Chief Scientific Officer, PlasmidFactory GmbH Date: Wed, Nov 19, 2025 Time: 17:00 CET / 16:00 GMT / 11:00 ET / 08:00 PT
November 5, 2025
1 of 86,295
Next
